Advanced in Type 2 Diabetes (T2D)

Dr. Douglas S. Denham

Family Medicine
San Antonio, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Advanced in Type 2 Diabetes (T2D)
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Douglas Denham is a primary care provider, practicing in Family Medicine in San Antonio, Texas. Dr. Denham is rated as an Advanced provider by MediFind in the treatment of Type 2 Diabetes (T2D). His top areas of expertise are Hypoparathyroidism, Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes (T2D), and Type 1 Diabetes (T1D). Dr. Denham is currently accepting new patients.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 8 clinical trials in the study of Type 2 Diabetes (T2D).

Specialties
Family Medicine
Licenses
Family Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

San Antonio, TX 78233

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype
A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Phase: Phase 1
A 2-Stage (Open-Label Followed by Randomized Double-Blind, Placebo-Controlled Stage), Phase 2 Trial of Setmelanotide in Patients With Specific Gene Variants in the Melanocortin-4 Receptor Pathway
A 2-Stage (Open-Label Followed by Randomized Double-Blind, Placebo-Controlled Stage), Phase 2 Trial of Setmelanotide in Patients With Specific Gene Variants in the Melanocortin-4 Receptor Pathway
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug
Study Phase: Phase 1
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 1, Open Label, Nonrandomized, Single-dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 in Subjects With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
A Phase 1, Open Label, Nonrandomized, Single-dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 in Subjects With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D With NovoLog® in Type 1 Diabetes Mellitus Patients
A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D With NovoLog® in Type 1 Diabetes Mellitus Patients
Enrollment Status: Completed
Publish Date: February 25, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, and Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01
A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, and Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01
Enrollment Status: Terminated
Publish Date: March 21, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)
A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)
Enrollment Status: Completed
Publish Date: November 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
Enrollment Status: Completed
Publish Date: October 30, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 16 Less Clinical Trials

19 Total Publications

Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study.
Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study.
Journal: Diabetes technology & therapeutics
Published: January 27, 2025
Similar Doctors
Distinguished in Type 2 Diabetes (T2D)
Dr. Laura E. Givens
Family Medicine
Distinguished in Type 2 Diabetes (T2D)
Dr. Laura E. Givens
Family Medicine

Centric Physicians Group PLLC

7400 Crestway Rd, 
San Antonio, TX 
 (2.7 miles away)
830-267-4575
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Givens is a primary care provider, practicing in Family Medicine in San Antonio, Texas. Dr. Givens is rated as a Distinguished provider by MediFind in the treatment of Type 2 Diabetes (T2D). Her top areas of expertise are Alzheimer's Disease, Type 2 Diabetes (T2D), Hypertension, and Familial Hypertension. Dr. Givens is currently accepting new patients.

Distinguished in Type 2 Diabetes (T2D)
Dr. Daniel H. Kellum
Family Medicine
Distinguished in Type 2 Diabetes (T2D)
Dr. Daniel H. Kellum
Family Medicine

Kellum Physician Partners PA

Schertz, TX 
 (6.0 miles away)
210-945-2121
Languages Spoken:
English, Filipino, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Kellum is a primary care provider, practicing in Family Medicine in Schertz, Texas. Dr. Kellum is rated as a Distinguished provider by MediFind in the treatment of Type 2 Diabetes (T2D). His top areas of expertise are Xanthoma, Familial Combined Hyperlipidemia, Cirrhosis, and Glucocorticoid-Remediable Aldosteronism. Dr. Kellum is currently accepting new patients.

Distinguished in Type 2 Diabetes (T2D)
Dr. Jesus G. Garcia-Gallegos
Family Medicine | Geriatrics
Distinguished in Type 2 Diabetes (T2D)
Dr. Jesus G. Garcia-Gallegos
Family Medicine | Geriatrics

Gmg Health Systems Associates PA

720 Pleasanton Rd, 
San Antonio, TX 
 (15.0 miles away)
210-921-3800
Languages Spoken:
English, French, German, Spanish
See accepted insurances
Accepting New Patients

Jesus Garcia-Gallegos is a primary care provider, practicing in Family Medicine and Geriatrics in San Antonio, Texas. Dr. Garcia-Gallegos is rated as a Distinguished provider by MediFind in the treatment of Type 2 Diabetes (T2D). His top areas of expertise are Type 2 Diabetes (T2D), Osteomyelitis in Children, Apparent Mineralocorticoid Excess, and Hyperaldosteronism. Dr. Garcia-Gallegos is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Denham's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile